$ATOS
ATOSSA THERAPEUTICS, INC. Stock $atos

$atos Overview Financials Valuation SEC Filings Company Website

2015 Q3 Form 10-Q Financial Statement

#000114420415064686 Filed on November 12, 2015

Income Statement

Concept	2015 Q3	2014 Q4	2014 Q3
Revenue	$0.00	$0.00	$3.426K
YoY Change	-100.0%	-100.0%	-95.53%
Cost Of Revenue	$313.4K	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Gross Profit	$458.8K	$0.00	$3.426K
YoY Change	13292.82%	-100.0%	-93.24%
Gross Profit Margin			100.0%
Selling, General & Admin	$3.756M	$1.720M	$2.326M
YoY Change	61.51%	-23.56%	-28.03%
% of Gross Profit	818.58%		67878.34%
Research & Development	$1.090M	-$750.0K	$923.2K
YoY Change	18.11%	-302.7%	187.49%
% of Gross Profit	237.63%		26945.97%
Depreciation & Amortization	$80.00K	$180.0K	$24.64K
YoY Change	224.64%	50.0%	-9.28%
% of Gross Profit	17.44%		719.29%
Operating Expenses	$4.846M	$980.0K	$3.249M
YoY Change	49.18%	-62.74%	-8.55%
Operating Profit	-$4.387M	-$980.0K	-$3.245M
YoY Change	35.2%	-62.45%	-7.33%
Interest Expense	$70.00K	$0.00	$151.00
YoY Change	46257.62%		15000.0%
% of Operating Profit
Other Income/Expense, Net	$69.35K		-$140.00
YoY Change	-49632.14%
Pretax Income	-$3.773M	-$3.330M	-$3.245M
YoY Change	16.27%	20.65%	-7.32%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$4.318M	-$5.810M	-$3.245M
YoY Change	33.05%	110.51%	-7.32%
Net Earnings / Revenue			-94728.4%
Basic Earnings Per Share
Diluted Earnings Per Share	-$28.80M	-$41.50M	-$23.21M
COMMON SHARES
Basic Shares Outstanding		24.56M shares	24.56M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2015 Q3	2014 Q4	2014 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$7.800M	$8.500M	$11.40M
YoY Change	-31.58%	34.92%	48.05%
Cash & Equivalents	$7.839M	$8.501M	$11.37M
Short-Term Investments
Other Short-Term Assets	$500.0K	$0.00	$300.0K
YoY Change	66.67%	-100.0%	-50.0%
Inventory	$170.9K	$9.276K	$0.00
Prepaid Expenses		$194.0K
Receivables	$1.055M	$298.0K	$0.00
Other Receivables	$0.00		$0.00
Total Short-Term Assets	$9.542M	$9.086M	$11.70M
YoY Change	-18.44%	34.37%	36.12%
LONG-TERM ASSETS
Property, Plant & Equipment	$484.5K	$136.7K	$200.0K
YoY Change	142.27%	-16.21%	-54.88%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$52.65K	$48.19K	$500.0K
YoY Change	-89.47%	32.23%	-88.75%
Total Long-Term Assets	$2.858M	$2.678M	$5.100M
YoY Change	-43.96%	-48.96%	4.36%
TOTAL ASSETS
Total Short-Term Assets	$9.542M	$9.086M	$11.70M
Total Long-Term Assets	$2.858M	$2.678M	$5.100M
Total Assets	$12.40M	$11.76M	$16.80M
YoY Change	-26.19%	-2.04%	24.61%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.179M	$513.0K	$400.0K
YoY Change	194.83%	106.75%	1184.89%
Accrued Expenses	$934.7K	$254.1K	$393.7K
YoY Change	137.41%	-13.95%	-71.88%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.300M	$2.214M	$1.500M
YoY Change	120.0%	57.98%	-22.77%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$0.00	$0.00
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.300M	$2.214M	$1.500M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$3.298M	$2.266M	$1.500M
YoY Change	119.89%	61.0%	-21.05%
SHAREHOLDERS EQUITY
Retained Earnings		-$35.17M
YoY Change		71.44%
Common Stock		$24.56K
YoY Change		32.25%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$9.059M	$9.498M	$15.20M
YoY Change
Total Liabilities & Shareholders Equity	$12.36M	$11.76M	$16.80M
YoY Change	-26.44%	-2.04%	24.61%

Cashflow Statement

Concept	2015 Q3	2014 Q4	2014 Q3
OPERATING ACTIVITIES
Net Income	-$4.318M	-$5.810M	-$3.245M
YoY Change	33.05%	110.51%	-7.32%
Depreciation, Depletion And Amortization	$80.00K	$180.0K	$24.64K
YoY Change	224.64%	50.0%	-9.28%
Cash From Operating Activities	-$3.480M	-$2.720M	-$2.980M
YoY Change	16.78%	2.64%	8.76%
INVESTING ACTIVITIES
Capital Expenditures	-$30.00K	-$50.00K	-$100.0K
YoY Change	-70.0%	-44.44%	-67.74%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$30.00K	-$50.00K	-$100.0K
YoY Change	-70.0%	-44.44%	-67.74%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-50.00K	-100.0K	150.0K
YoY Change	-133.33%	-107.19%	-98.19%
NET CHANGE
Cash From Operating Activities	-3.480M	-2.720M	-2.980M
Cash From Investing Activities	-30.00K	-50.00K	-100.0K
Cash From Financing Activities	-50.00K	-100.0K	150.0K
Net Change In Cash	-3.560M	-2.870M	-2.930M
YoY Change	21.5%	112.59%	-155.81%
FREE CASH FLOW
Cash From Operating Activities	-$3.480M	-$2.720M	-$2.980M
Capital Expenditures	-$30.00K	-$50.00K	-$100.0K
Free Cash Flow	-$3.450M	-$2.670M	-$2.880M
YoY Change	19.79%	4.3%	18.52%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	934675	USD
CY2014Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	247207	USD
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	444861	USD
CY2015Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1156000	USD
CY2015Q3	us-gaap	Assets Current AssetsCurrent	9542010	USD
CY2014Q4	us-gaap	Inventory Net InventoryNet	39788	USD
CY2015Q3	us-gaap	Inventory Net InventoryNet	170860	USD
CY2014Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	297958	USD
CY2015Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1055059	USD
CY2015Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1768812	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	357532	USD
CY2015Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	484544	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	9085671	USD
CY2014Q4	us-gaap	Assets Assets	11764002	USD
CY2015Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1179329	USD
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	594357	USD
CY2014Q3	us-gaap	Cost Of Revenue CostOfRevenue	0	USD
CY2014Q3	us-gaap	Gross Profit GrossProfit	3426	USD
CY2015Q3	us-gaap	Selling Expense SellingExpense	738036	USD
CY2014Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-3245395	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8500718	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	45867	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	71099	USD
CY2014Q4	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	351961	USD
CY2015Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7839439	USD
CY2015Q3	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	509375	USD
CY2015Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	52649	USD
CY2015Q3	us-gaap	Stockholders Equity StockholdersEquity	9059097	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	9498127	USD
CY2015Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	12357390	USD
CY2014Q4	us-gaap	Liabilities Liabilities	2265875	USD
CY2015Q3	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	0	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	11764002	USD
CY2015Q3	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	0	USD
CY2015Q3	us-gaap	Liabilities Liabilities	3298293	USD
CY2014Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	48193	USD
CY2014Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	76025	USD
CY2014Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	49216	USD
CY2015Q3	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	5688	USD
CY2014Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	2483	USD
CY2015Q3	us-gaap	Cost Of Revenue CostOfRevenue	313406	USD
CY2015Q3	us-gaap	Gross Profit GrossProfit	458838	USD
CY2015Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-4318111	USD
CY2015Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	-4318111	USD
CY2015Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.15
CY2015Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	28766012	shares
CY2015Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1090349	USD
CY2015Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3017909	USD
CY2015Q3	us-gaap	Operating Expenses OperatingExpenses	4846294	USD
CY2015Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-4387456	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	5339669	USD
	us-gaap	Cost Of Revenue CostOfRevenue	3376071	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-10798727	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Net Income Loss NetIncomeLoss	-10798727	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.39
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	27500855	shares
	us-gaap	Operating Expenses OperatingExpenses	12828874	USD
CY2014Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	-3245395	USD
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	23860843	shares
	us-gaap	Selling Expense SellingExpense	743597	USD
	us-gaap	Operating Expenses OperatingExpenses	8880138	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-8842713	USD
CY2014Q3	us-gaap	Operating Expenses OperatingExpenses	3248681	USD
CY2014Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3245255	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	37425	USD
	us-gaap	Cost Of Revenue CostOfRevenue	0	USD
CY2014Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.13
CY2014Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	24537379	shares
CY2014Q3	us-gaap	Selling Expense SellingExpense	282374	USD
CY2014Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	923169	USD
CY2014Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2043138	USD
	us-gaap	Gross Profit GrossProfit	37425	USD
	us-gaap	Selling Expense SellingExpense	2016951	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-8844902	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Net Income Loss NetIncomeLoss	-8844902	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.37
	us-gaap	Operating Income Loss OperatingIncomeLoss	-10865276	USD
CY2015Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	69345	USD
CY2014Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-140	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	66549	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2189	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	326769	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	205879	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	99295	USD
	atos	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	-39608	USD
	atos	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	11298	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-5774	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	566118	USD
	atos	Increase Decrease In Product Recall Liabilities IncreaseDecreaseInProductRecallLiabilities	-208108	USD
	atos	Increase Decrease In Product Recall Liabilities IncreaseDecreaseInProductRecallLiabilities	0	USD
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-11274	USD
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-27720	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-7836146	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-9999872	USD
	us-gaap	Payments To Acquire Furniture And Fixtures PaymentsToAcquireFurnitureAndFixtures	102530	USD
	us-gaap	Payments To Acquire Furniture And Fixtures PaymentsToAcquireFurnitureAndFixtures	95196	USD
	us-gaap	Payments To Acquire Software PaymentsToAcquireSoftware	184979	USD
	us-gaap	Payments To Acquire Software PaymentsToAcquireSoftware	15553	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	5032090	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-661279	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6342161	USD
CY2014Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11374251	USD
	us-gaap	Profit Loss ProfitLoss	-8844902	USD
	us-gaap	Interest Paid InterestPaid	2343	USD
	us-gaap	Interest Paid InterestPaid	284	USD
	us-gaap	Profit Loss ProfitLoss	-10798727	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	545115	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	703726	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	380977	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	249744	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	80870	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	1188193	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-29051	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1878795	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	131072	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-45555	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	191106	USD
	atos	Noncash Reclass Of Prepaid License Fees NoncashReclassOfPrepaidLicenseFees	15000	USD
	atos	Amortization Of Commitment Shares Issued For Shares Distributed For Capital Contribution AmortizationOfCommitmentSharesIssuedForSharesDistributedForCapitalContribution	0	USD
	atos	Amortization Of Commitment Shares Issued For Shares Distributed For Capital Contribution AmortizationOfCommitmentSharesIssuedForSharesDistributedForCapitalContribution	453836	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	42512	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	4456	USD
	atos	Noncash Reclass Of Prepaid License Fees NoncashReclassOfPrepaidLicenseFees	0	USD
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	74800	USD
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0	USD
CY2015Q3	atos	Working Capital WorkingCapital	6200000	USD
CY2015Q3	us-gaap	Prepaid Advertising PrepaidAdvertising	12500	USD
CY2014Q4	us-gaap	Prepaid Advertising PrepaidAdvertising	50000	USD
CY2015Q3	us-gaap	Supplies Supplies	10481	USD
CY2014Q4	us-gaap	Supplies Supplies	14976	USD
CY2015Q3	us-gaap	Prepaid Insurance PrepaidInsurance	41668	USD
CY2014Q4	us-gaap	Prepaid Insurance PrepaidInsurance	87633	USD
CY2015Q3	us-gaap	Deposit Assets DepositAssets	39218	USD
CY2014Q4	us-gaap	Deposit Assets DepositAssets	25000	USD
CY2015Q3	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	10021	USD
CY2014Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	31330	USD
CY2015Q3	atos	Prepaid Maintenance And Support Service Fee PrepaidMaintenanceAndSupportServiceFee	46568	USD
CY2014Q4	atos	Prepaid Maintenance And Support Service Fee PrepaidMaintenanceAndSupportServiceFee	38268	USD
CY2015Q3	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	718953	USD
CY2014Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	522813	USD
CY2015Q3	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	121596	USD
CY2014Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	93665	USD
CY2015Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	356005	USD
CY2014Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	258946	USD
CY2015Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	840549	USD
CY2014Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	616478	USD
CY2015Q3	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	1630000	USD
CY2014Q4	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	1630000	USD
CY2015Q3	us-gaap	Finite Lived License Agreements Gross FiniteLivedLicenseAgreementsGross	200000	USD
CY2014Q4	us-gaap	Finite Lived License Agreements Gross FiniteLivedLicenseAgreementsGross	200000	USD
CY2015Q3	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	203890	USD
CY2014Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	203038	USD
CY2015Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	265078	USD
CY2014Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	112393	USD
CY2015Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2033890	USD
CY2014Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2033038	USD
CY2015Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	53515	USD
CY2015Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	227130	USD
CY2015Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	198628	USD
CY2015Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	169934	USD
CY2015Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	169015	USD
CY2015Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	950590	USD
CY2015Q3	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	741596	USD
CY2014Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	752828	USD
CY2015Q3	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	236582	USD
CY2014Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	194224	USD
CY2014Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	16337	USD
CY2015Q3	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	737991	USD
CY2014Q4	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	174398	USD
CY2015Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	106802	USD
CY2015Q3	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	89882	USD
CY2015Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2015Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2015Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014Q2	atos	Percentage Of Common Stock Outstanding PercentageOfCommonStockOutstanding	0.020	pure
CY2014Q2	atos	Entitled To Receive Worth Of Common Stock EntitledToReceiveWorthOfCommonStock	30.00
CY2014Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	254126	USD
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2015Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	30446260	shares
CY2015Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	30446260	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	24564058	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	24564058	shares
CY2015Q3	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	USD
CY2015Q3	us-gaap	Cash Uninsured Amount CashUninsuredAmount	7864439	USD
CY2014Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	8250718	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	2693384	shares
CY2015Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	317986	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	703726	USD
CY2014Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	147399	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	545115	USD
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	500	USD
CY2015Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0	USD
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	406	USD
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.53
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	2.01
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.31
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	3.38
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	2.37
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y7M6D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	559047	shares
	atos	Stock Issued During Period Shares Stock Options Exercised1 StockIssuedDuringPeriodSharesStockOptionsExercised1	0	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y10M24D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y7M6D
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	344000	USD
	atos	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue	63223	USD
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1618524	shares
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	4047912	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3675634	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1640822	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0	USD
	atos	Share Based Compensation Arrangement By Share Based Payment Award Options Granted In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue	0	USD
CY2015Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	2788885	shares
CY2015Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	2250594	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P2Y10M6D
CY2015Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q3	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	275000	USD
CY2014Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	0	USD
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	0	USD
	atos	Purchases Of Equipment Recorded In Accounts Payable PurchasesOfEquipmentRecordedInAccountsPayable	128875	USD
	atos	Purchases Of Equipment Recorded In Accounts Payable PurchasesOfEquipmentRecordedInAccountsPayable	0	USD
	us-gaap	Nature Of Operations NatureOfOperations	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="center"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt">NOTE 1: NATURE OF OPERATIONS</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt"> </font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="BACKGROUND-COLOR: transparent">Atossa Genetics Inc. (the “Company”) was incorporated on April 30, 2009 in the State of Delaware. The Company was formed to develop and market medical devices, laboratory tests and therapeutics to address breast health conditions. The Company’s fiscal year ends on December 31st.</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="BACKGROUND-COLOR: transparent">The Company’s current therapeutic programs include Afimoxifene Gel and Fulvestrant administered through the Company’s patented intraductal Microcatheters, both of which are in Phase II clinical development. The Company’s medical devices consist primarily of its ForeCYTE Breast Aspirator (formerly called the Mammary Aspirate Specimen Cytology Test System, or MASCT), the FullCYTE Breast Aspirator and the intraductal Microcatheters. In December 2011, the Company established The National Reference Laboratory for Breast Health, Inc., the NRLBH, as a wholly-owned subsidiary which performs nipple aspirate fluid (“NAF”) cytology testing on NAF specimens, including those collected with the Company’s breast aspirator devices, and pharmacogenomics tests. The NRLBH is certified by College of American Pathologists (CAP) and by Clinical Laboratory Improvement Amendments (CLIA) and it is certified under ISO 15189:2012.</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Since its inception, the Company has been dependent upon the receipt of capital investment to fund its continuing activities. In addition to the normal risks associated with a new business venture, there can be no assurance that the Company’s business plan will be successfully executed. The Company’s ability to execute its business plan will depend on its ability to obtain additional financing and achieve a profitable level of operations. There can be no assurance that sufficient financing will be obtained. Further, the Company cannot give any assurance that it will generate substantial revenue or that its business operations will prove to be profitable.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt">Use of Estimates:</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt"> </font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. </font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2015Q3	atos	Prepaid Professional Fees PrepaidProfessionalFees	41196	USD
CY2014Q4	atos	Prepaid Professional Fees PrepaidProfessionalFees	0	USD
CY2015Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	8244423	shares
CY2015Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12651832	shares
CY2014Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9497658	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12651832	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9497658	shares
CY2014Q3	us-gaap	Other Commitments Description OtherCommitmentsDescription	On September 1, 2014, the NRLBH entered into a three year agreement with TME Research LLC (TME) which requires TME to provide to the NRLBH 100 tissue specimens in connection with the development of the NextCYTE test. Fees payable to TME under the agreement includes $99,600 up front, $31,500 upon supplying the first 25 specimens and $31,500 at the time of final delivery of all specimens. The agreement is terminable with 60 days prior written notice or immediately upon a material breach.
CY2015Q3	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	317986	USD
CY2014Q3	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	147399	USD
	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	703726	USD
	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	545114	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	350000	shares
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	9498557	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	13155745	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	49215	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	0	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	9449342	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	13155745	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-110749	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-287509	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	275000	USD
CY2015Q3	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	177822	USD
CY2014Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	109653	USD
CY2015Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	1182777	USD
CY2014Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	564456	USD
CY2015Q3	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	625499	USD
CY2014Q3	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	16111	USD

Files In Submission

Name	View Source	Status
0001144204-15-064686-index-headers.html	Edgar Link	pending
0001144204-15-064686-index.html	Edgar Link	pending
0001144204-15-064686.txt	Edgar Link	pending
0001144204-15-064686-xbrl.zip	Edgar Link	pending
atos-20150930.xml	Edgar Link	completed
atos-20150930.xsd	Edgar Link	pending
atos-20150930_cal.xml	Edgar Link	unprocessable
atos-20150930_def.xml	Edgar Link	unprocessable
atos-20150930_lab.xml	Edgar Link	unprocessable
atos-20150930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v422970_10q.htm	Edgar Link	pending
v422970_ex10-1.htm	Edgar Link	pending
v422970_ex10-2.htm	Edgar Link	pending
v422970_ex31-1.htm	Edgar Link	pending
v422970_ex31-2.htm	Edgar Link	pending
v422970_ex32-1.htm	Edgar Link	pending
v422970_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ATOS
ATOSSA THERAPEUTICS, INC. Stock $atos

2015 Q3 Form 10-Q Financial Statement

#000114420415064686 Filed on November 12, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ATOS ATOSSA THERAPEUTICS, INC. Stock $atos

2015 Q3 Form 10-Q Financial Statement

#000114420415064686 Filed on November 12, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ATOS
ATOSSA THERAPEUTICS, INC. Stock $atos